Home » News » Clinical Intelligence » Pfizer initiates phase I trial for Hemophilia drug

Pfizer initiates phase I trial for Hemophilia drug

Monday, January 9, 2012

Pfizer has initiated a phase I clinical trial for PF-05280602, an engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.

“We are very excited to see the lead candidate from Catalyst’s hemostasis franchise advance into human clinical trials,” said Nassim Usman, Ph.D., CEO of Catalyst Biosciences.

The drug has been engineered to provide improved acute and prophylactic treatment for hemophilia A and B patients with inhibitors. The initiation of phase I clinical trials triggered $7 million in milestone payments to Catalyst Biosciences from Pfizer.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!